logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
20/08/2025
WuXi AppTec: Net profit was 2.34 billion yuan in the first half of the year, up from 1.5 billion yuan in the same period last year.
Latest
2 m ago
With Huang Medicine: Enroll patients in the SANOVO China Phase III study for combined therapy with Xalkori and Tarceva for first-line treatment of specific lung cancer patients.
2 m ago
On the morning of August 20th, Hutchison Pharma and Walrysha Pharmaceuticals announced on the Hong Kong Stock Exchange that the SANOVO China Phase III study for the combination therapy of Walrysha and Terisha for first-line treatment of specific non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations and MET overexpression has completed patient enrollment. The last patient for the study was enrolled on August 18th, 2025. The top-line results of the SANOVO study are expected to be announced in the second half of 2026 and will be submitted for publication at an appropriate academic conference shortly thereafter. If the desired results are achieved, Hutchison Pharma and Walrysha will initiate plans to submit a new indication application to the National Medical Products Administration.
4 m ago
Intel surged 28% this month, with its valuation reaching levels last seen during the internet bubble period.
4 m ago
After months of volatility, Intel's stock finally rewarded the patience of the bulls. However, the sudden rebound of the stock also brought a worrying side effect: the valuation is so high that it hasn't been this high since the internet bubble era over twenty years ago. It is reported that the US government is in talks to invest in Intel, and SoftBank Group will buy $2 billion worth of shares. As a result of these news, the struggling chip manufacturer's stock price has risen by 28% this month, with the market value increasing by approximately $24 billion. Data shows that Intel's stock price is now trading at 53 times the expected earnings for the next 12 months, the highest level since early 2002. "This stock now looks incredibly expensive," said Wayne Kaufman, chief market analyst at Phoenix Financial Services. "Such a high price-earnings ratio is a bet that the government will heavily promote Intel and eventually make it a winner."
5 m ago
The South Korean composite stock price index fell by 2.1% to 3,086.31 points.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.